ERG expression and prostatic adenocarcinoma

Ferlay J, Parkin DM, Steliarova-Foucher E (2010) Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 46:765–781. doi: 10.1016j/ejca.2009.12.014

Perner S, Demichelis F, Beroukhim R et al (2006) TMPRSS2:ERG fusion-associated deletions provide insight into heterogeneity of prostate cancer. Cancer Res 66(17):8337–8341. doi: 10.1158/0008-5472.CAN-06-1468

Wang J, Cai Y, Ren C, Ittmann M (2006) Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer. Cancer Res 66:8347–8351. doi: 10.1158/0008-5472.CAN-06-1966

Clark JP, Cooper CS (2009) ETS gene fusions in prostate cancer. Nat Rev Urol 6:429–439. doi: 10.1038/nrurol.2009.127

Park K, Tomlins SA, Mudaliar KM et al (2010) Antibody-based detection of ERG rearrangement-positive prostate cancer. Neoplasia 12(7):590–598. doi: 10.1593/neo.10726

Falzarano SM, Zhou M, Carver P et al (2011) ERG gene rearrangement status in prostate cancer detected by immunohistochemistry. Virchows Arch 459(4):441–447. doi: 10.1007/s00428-011-1128-4

Chaux A, Albadine R, Toubaji A et al (2011) Immunohistochemistry for ERG expression as a surrogate for TMPRSS2-ERG fusion detection in prostatic adenocarcinomas. Am J Surg Pathol 35:1014–1020. doi: 10.1097/PAS.0b013e31821e8761

R Core Team (2012). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0, URL http://www.R-project.org/ .

Verzani J (2004) Using R for introductory statistics. Chapman & Hall/CRC, Boca Raton

Mosquera JM, Mehra R, Regan MM et al (2009) Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the united states. Clin Cancer Res 15(14):4706–4711. doi: 10.1158/1078-0432.CCR-08-2927

Magi-Galluzzi C, Tsusuki T, Elson P et al (2011) TMPRSS2-ERG gene fusion prevalence and class are significantly different in prostate cancer of Caucasian, African-American and Japanese patients. Prostate 71:489–497. doi: 10.1002/pros.21265

Miyagi Y, Sasaki T, Fujinami K et al (2010) ETS family-associated gene fusions in Japanese prostate cancer: analysis of 194 radical prostatectomy samples. Mod Pathol 23:1492–1498. doi: 10.1038/modpathol.2010.149

Minner S, Enodien M, Sirma H et al (2011) ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy. Clin Can Res 17(18):5878–5888. doi: 10.1158/1078-0432.CCR-11-1251

Mosquera JM, Perner S, Genega EM et al (2008) Characterization of TMPRSS2-ERG fusion high-grade prostatic intraepithelial neoplasia and potential clinical implications. Clin Cancer Res 14(11):3380–3385. doi: 10.1158/1078-0432.CCR-07-5194

Tomlins SA, Palanisamy N, Siddiqui J, Chinnaiyan AM, Kunju LP (2012) Antibody-based detection of ERG rearrangements in prostate core biopsies, including diagnostically challenging cases. Arch Pathol Lab Med 136:935–946. doi: 10.5858/arpa.2011-0424-OA

Han B, Mehra R, Lonigro R et al (2009) Fluorescent in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression. Mod Pathol 22(8):1083–1093. doi: 10.1038/modpathol.2009.69

Falzarano SM, Navas M, Simmerman K et al (2010) ERG rearrangement is present in a subset of transition zone prostatic tumors. Mod Pathol 23:1499–1506. doi: 10.1038/modpathol.2010.150

Van Leenders GJ, Boormans JL, Vissers CJ et al (2011) Antibody EPR3864 is specific for ERG genomic fusions in prostate cancer: implications for pathological practice. Mod Pathol 24(8):1128–1138. doi: 10.1038/modpathol.2011.65

Demichelis F, Fall K, Perner S et al (2007) TMPRSS2-ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene 26(31):4596–4599. doi: 10.1038/sj.onc.1210237

Furusato B, Tan S-H, Young D et al (2010) ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification. Prostate Cancer Prostatic Dis 13(3):228–237. doi: 10.1038/pcan.2010.23

He H, Magi-Galluzzi C, Li J et al (2011) The diagnostic utility of novel immunohistochemical marker ERG in the workup of prostate biopsies with “atypical glands suspicious for cancer”. Am J Surg Pathol 35(4):608–614. doi: 10.1097/PAS.0b013e31820bcd2d

Yaskiv O, Zhang X, Simmerman K et al (2011) The utility of ERG/p63 double immunohistochemical staining in the diagnosis of limited cancer in prostate needle biopsies. Am J Surg Pathol 35(7):1062–1068. doi: 10.1097/PAS.0b013e318215cc03

Jiang Z, Li C, Fischer A, Dresser K, Woda BA (2005) Using an AMACR (P504S)/34bE12/p63 cocktail for the detection of small focal prostate carcinoma in needle biopsy specimens. Am J Clin Pathol 123:231–236

Perner S, Mosquera JM, Demichelis F et al (2007) TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. Am J Surg Pathol 31:882–888

Scheble VJ, Braun M, Beroukhim R et al (2010) ERG rearrangement is specific to prostate cancer and does not occur in any other common tumor. Mod Pathol 23:1061–1067. doi: 10.1038/modpathol.2010.87

Miettinen M, Wang Z-F, Anders P et al (2011) ERG transcription factor as an immunohistochemical marker for vascular endothelial tumors and prostatic carcinoma. Am J Surg Pathol 35:432–441. doi: 10.1097/PAS.0b013e318206b67b